JP5422569B2 - 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類 - Google Patents

凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類 Download PDF

Info

Publication number
JP5422569B2
JP5422569B2 JP2010547078A JP2010547078A JP5422569B2 JP 5422569 B2 JP5422569 B2 JP 5422569B2 JP 2010547078 A JP2010547078 A JP 2010547078A JP 2010547078 A JP2010547078 A JP 2010547078A JP 5422569 B2 JP5422569 B2 JP 5422569B2
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
independently
oxo
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010547078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011512367A5 (enExample
JP2011512367A (ja
Inventor
マルクス・フォールマン
フォルクマー・ヴェーナー
ジャン−ミシェル・アルタンブルジェ
ジルベール・ラサル
ジャン−パスカル・エロル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011512367A publication Critical patent/JP2011512367A/ja
Publication of JP2011512367A5 publication Critical patent/JP2011512367A5/ja
Application granted granted Critical
Publication of JP5422569B2 publication Critical patent/JP5422569B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010547078A 2008-02-21 2009-02-10 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類 Expired - Fee Related JP5422569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290166.1 2008-02-21
EP08290166 2008-02-21
PCT/EP2009/000902 WO2009103439A1 (en) 2008-02-21 2009-02-10 Chlorothiophene-isoxazoles as inhibitors of coagulation factors xa and thrombin

Publications (3)

Publication Number Publication Date
JP2011512367A JP2011512367A (ja) 2011-04-21
JP2011512367A5 JP2011512367A5 (enExample) 2012-03-22
JP5422569B2 true JP5422569B2 (ja) 2014-02-19

Family

ID=39345612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010547078A Expired - Fee Related JP5422569B2 (ja) 2008-02-21 2009-02-10 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類

Country Status (4)

Country Link
US (1) US8835653B2 (enExample)
EP (1) EP2280964B1 (enExample)
JP (1) JP5422569B2 (enExample)
WO (1) WO2009103439A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162365A1 (en) 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
CN103562166B (zh) 2011-05-27 2016-03-16 默克专利股份有限公司 1-溴-3-卤-2-环烷基苯化合物
EP2907806A1 (en) * 2014-02-14 2015-08-19 Universita Degli Studi Di Genova New compounds as selective PDE4D inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9322976D0 (en) * 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
US6313242B1 (en) * 1996-05-20 2001-11-06 Fina Technology, Inc. Stereorigid bis-fluorenyl metallocenes
US6274620B1 (en) * 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
WO2001038309A1 (en) * 1999-11-24 2001-05-31 Cor Therapeutics, Inc. β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
US7414134B2 (en) * 2004-10-12 2008-08-19 Amgen Inc. B1 bradykinin receptor antagonists
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien

Also Published As

Publication number Publication date
US20110112074A1 (en) 2011-05-12
WO2009103439A1 (en) 2009-08-27
EP2280964B1 (en) 2012-08-29
US8835653B2 (en) 2014-09-16
JP2011512367A (ja) 2011-04-21
EP2280964A1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
US20110039829A1 (en) Pyrazole-carboxamide derivatives as p2y12 antagonists
JP5422570B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−アミド類
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체
AU2004238499A1 (en) Indazole-derivatives as factor Xa inhibitors
JP2007535497A (ja) 第Ｘａ因子阻害剤としてのβ−アミノ酸誘導体
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
JP4658940B2 (ja) 第Ｘａ因子阻害剤としてのベンゾイミダゾール誘導体
JP4733642B2 (ja) 第Ｘａ因子阻害剤としてのアザインドール−誘導体
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
HK1156607B (en) Chlorothiophene-amides as inhibitors of coagulation factors xa and thrombin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120206

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131125

LAPS Cancellation because of no payment of annual fees